MedPage Today (5/25, Monaco) reports, “When combined with psychological support, just one dose of psilocybin therapy improved treatment-resistant depression,” researchers concluded in a 233-patient, phase IIb study revealing that “the 25-mg dose demonstrated a statistically significant improvement as early as the second day,” and “therapeutic benefits were also sustained through week 12 of follow-up.” The findings were presented at the American Psychiatric Association 2022 Annual Meeting.(SOURCE: APA Headlines)